Objectives: Few studies report incidence of mild cognitive impairment (MCI) and other mild cognitive disorders (MCD) in cohorts in their 60s, at an age when diagnoses are less stable. The authors' goal was to estimate the incidence and prevalence of MCI and MCD, characterize subgroups with stable vs nonstable diagnoses, and evaluate the impact of diagnosis on daily life in a young-old cohort. Methods: A community-based cohort age 60 to 64 years in 1999 (n 5 2551) was monitored for 8 years and assessed every 4 years. A two-stage sampling design was used to identify MCI and MCD through a neuropsychological and neurological assessment. A panel of physicians blind to previous diagnoses reviewed each case using published criteria.
Introduction
Most of the research on mild cognitive impairment (MCI) and related definitions of preclinical dementia syndromes has been conducted in adults age 70 years or older [1] . There are few studies available from which to ascertain the incidence, prevalence, and course of MCI in individuals in their 60s, the stability of diagnoses at this age, and the impact cognitive impairment has on employment and everyday life. Characterizing MCI clinically in its earliest stages is required to provide a complete picture of the epidemiology of neurocognitive disorders and may assist in identifying their etiology and in guiding treatment decisions.
Conversion rates of MCI to Alzheimer's disease (AD) and other dementias are highly age dependent and variable [2] . Unless patients who ultimately develop dementia are assessed prior to diagnosis of a mild cognitive disorder (MCD), the true duration of the MCI stage at the population level is not estimable. Our aim is to characterize cognitive impairment at an age when many older adults remain in the workforce and are actively engaged in their community. Following results from our previous two waves [3, 4] , we estimate the incidence of MCI [5] and a broader category of MCD [3] in a young-old cohort in their 60s and evaluate factors associated with the stability of diagnoses in this age range. We also evaluate the association between MCDs and perceived memory difficulties, reports of attending a general practitioner for memory difficulties, and problems with instrumental activities of daily living (IADLs).
Methods

Study participants
Participants were sampled randomly from the electoral rolls for Canberra, ACT, and Queanbeyan, NSW, Australia, as part of the Personality and Total Health (PATH) Through Life Project [6] . They were asked to complete a questionnaire under the supervision of a professional interviewer. Cognitive and physical tests were also carried out and a cheek swab was taken from which DNA could be extracted. Written informed consent was obtained from all participants prior to involvement in the study, and the Australian National University Human Research Ethics Committee approved the study. The oldest cohort is the focus of this study and was 60 to 64 years at wave 1; interviews were conducted 
Screening
At each wave, the same predetermined cutoff on a cognitive screening battery was used to screen participants into a substudy on MCDs and dementia. Participants from the full cohort were selected for clinical assessment if they had any of the following: (i) a Mini-Mental State Examination (MMSE) [7] score 25, (ii) a score below the fifth percentile score from wave 1 on immediate or delayed recall of the California Verbal Learning Test [8] (immediate or delayed score of ,4 and ,2, respectively), or (iii) a score below the fifth percentile on two or more of the following tests: Symbol-Digit Modalities Test [9] (,33) or Purdue Pegboard with both hands [10] (wave 1, ,8; wave 2, ,7), or simple reaction time [11] (third set of 20 trials; wave 1, .310 ms; wave 2, .378 ms).
Clinical assessment
The clinical assessment involved a Structured Clinical Assessment for Dementia (available from us) by one of two physicians, a neuropsychological assessment, and the Clinical Dementia Rating Scale [12] . Information was also gathered on medical history related to cognitive function, duration of symptoms, medical history from medical practitioners and family, current treatment, and psychiatric history. Depression was assessed using the self-administered Patient Health Questionnaire from the Primary Care Evaluation of Mental Disorders (PRIME-MD) [13] . Informant interviews were conducted when possible. Participants receiving any clinical diagnosis were referred to their family doctor for laboratory investigations. The research protocol included magnetic resonance imaging for all consenting participants. The neuropsychological assessment included frontal executive function (Trails A and B [14] , Verbal Fluency [15] , and Clock Drawing [16] ), language (Boston Naming Short Form [17] ), constructional praxis from the Consortium to Establish a Registry for Alzheimer's Disease battery [18] , memory (Rey Auditory Verbal Learning Test with verbal recall and recognition [19] ) recall of constructional praxis for nonverbal memory, and agnosia [20] .
Clinicians used clinical checklists, data from the neuropsychological assessment, neuropsychiatric history, and medical history to formulate consensus diagnoses. Criteria for the following diagnoses were applied: MCI [5, 21] , age-associated memory impairment [22] , age-associated cognitive decline [23] , mild neurocognitive disorder [24] , impairment on the Clinical Dementia Rating Scale [12] , and other cognitive disorder [24] . Diagnostic and Statistical Manual of Mental Disorders, 4th edition, criteria were used to assess dementia and delirium [24] . The Petersen criteria for MCI were used at waves 1 and 2 [21] , whereas the Winblad criteria [5] were used at wave 3. For all other categories, the same criteria were used for all three waves and have been published by our group elsewhere [4] . A description of criteria is included in the online supplementary material. Important for this study, clinicians were blind to the presence or lack of diagnosis obtained at waves 1 and 2.
Assessment of self-reported impact of memory on function
At waves 1 and 2 participants were asked: Do you feel you can remember things as well as you used to? That is, is your memory the same as it was earlier in life? If they answered no, then they were asked: Does this memory problem interfere in any way with your day-to-day life? And have you seen a doctor about your memory? IADLs were assessed at wave 3 with items adapted from the U.S. Health and Retirement Study [25] and included difficulty reading a map, preparing meals, shopping for groceries, and making telephone calls.
Health measures
During the interview, data were collected on history of neurological disorders and thyroid conditions. Information on medication for hypercholesterolemia, smoking status, and diabetes mellitus and its treatment were obtained via self-report, and blood pressure was measured. These variables were combined with age and sex to compute a Framingham cardiovascular risk score for each participant [26] .
Data analysis
Group comparisons were made with analysis of variance for continuous variables or c 2 tests for frequencies. To identify factors associated with diagnostic instability, we evaluated whether a range of factors previously associated with cognitive fluctuation and cognitive decline in the literature differed among groups. These included both depression at baseline and variability in depression over time [27] , baseline anticholinergic medication and variability in anticholinergic burden [28, 29] , history of thyroid disorder [30, 31] , history of neurological disorder, and baseline cardiovascular risk profile [32, 33] .
To establish predicted prevalence and incidence rates for the cohort, predictive regression models were built based on the relationship between the screening measures and the clinical data for the subsample for which diagnostic data were available using methods described previously [3] . It was necessary to compute prevalence among participants who screened positive but who did not undertake the clinical assessment, and to estimate the false negatives in the sample that screened negative. Using the clinical diagnoses as the gold standard, logistic regressions with age, sex, and screening measures as predictor variables were built. For each diagnostic criterion, a predictive score defined as the probability of positive diagnosis was derived and a cutoff point was chosen so that the number of predicted diagnoses was the same as the number of observed diagnoses under the criterion in the subsample. This cutoff point was then applied to the predictive score of those who screened positive but did not undertake the clinical assessment and those who screened negative. The final prevalence estimate was a sum of those receiving clinical diagnoses, those estimated to receive a diagnosis among the group that screened positive but did not receive a diagnosis, and those estimated to have been falsely screened as negative. To estimate the influence of attrition on the overall incidence rates data were imputed (using the expectation maximization algorithm) for 269 participants not monitored up from wave 2 to wave 3. Imputation was estimated using wave 1 and wave 2 cognition data, gender, and age.
The impact of attrition on estimates was evaluated by applying the predictive regression equations to the subgroups' most recent cognitive assessment data (wave 2) to estimate conservatively the proportion lost to follow-up with likely cognitive impairment.
Confidence intervals and standard errors for the prevalence estimate were estimated using bootstrap techniques. The logistic regression linking the diagnostic data and the screening data was fitted to 1000 bootstrap samples, and the population prevalence estimate was then calculated as the average of prevalence estimates across bootstrap samples. The 95% confidence interval was calculated by taking the 2.5th and 97.5th percentile of the bootstrap prevalence estimates. Analyses were conducted in IBM SPSS19 (Armok, NY, USA) and STATA version 9.0 (College Station, TX, USA).
Results
Sample size and demographics
At wave 3, the sample had a mean age of 70.60 years (standard deviation [SD], 1.50 years; range, 68-72 years), including 1020 males (51.7%). The sample had a mean of 13.98 years (SD, 2.7 years) of education.
Prevalence and incidence rates derived from statistical modeling
Incidence rates were estimated from the 2047 participants who were free from clinical diagnosis at wave 2. Of these individuals, 1838 were available for assessment at wave 3. Using the statistical estimates based on the screening measures applied to the entire sample, an estimated 141 (7.7%) participants converted to MCI and 183 (10.0%) converted to MCD during 4 years, indicating an incidence rate of 19.18 cases of MCI/1000 person-years and 24.89 cases of MCD/1000 person-years. Rates for conversion to MCI and MCD were higher for males (MCI, 9.3%; MCD, 11.7%) than females (MCI, 5.9%; MCD, 8.2%; P , .01). Of participants with statistically derived diagnoses who screened negative and therefore did not undergo a clinical assessment, 73 received a diagnosis of MCI and 95 received a diagnosis of MCD. The statistically estimated prevalence rates of MCDs in the cohort at wave 3 (not including imputed data from those lost at wave 2) are shown in Table 1 .
In the subsample lost to attrition (n 5 269), it was estimated that 33 (12.3%) progressed to MCI and 28 (10.4%) to MCD. Combining these predicted conversions with the full wave 3 sample, the incidence rate was calculated to 
Classification of stable and unstable MCD and MCI
All participants with an MCI/MCD diagnosis at any point in the study (MCI, n 5 149; MCD, n 5 93) were classified as stable, unstable, or new cases (Table 2 [34] [35] [36] ). Participants with a first diagnosis of any MCD/MCI at wave 3 were classified as new cases (any MCD, n 5 31; MCI, n 5 33). Of the participants with previous diagnoses of any MCD/ MCI, stable cases were defined as those with consecutive diagnoses across multiple assessments [34] without reversion to normalcy [35, 36] (any MCD, n 5 42; MCI, n 5 15). The remaining participants were classified unstable and comprised those with a prior diagnosis who had reverted to normalcy at wave 3, and those with a current diagnosis but nonconsecutive prior diagnoses (any MCD, n 5 76; MCI, n 5 40). Participants who progressed to dementia were categorized separately (n 5 8).
Characteristics of normal and clinical groups
Baseline demographic and cognitive characteristics of participants who remained without diagnosis and those diagnosed with MCI, any MCD, and dementia are shown in Table 3 . During the entire 8 years of follow-up, 187 participants received a diagnosis of any MCD (149 of whom were available at wave 3) and eight participants progressed to dementia. Of the participants diagnosed with an MCD during the study, approximately half demonstrated diagnostic instability, reverting to normal cognitive status during wave 3 ( Fig. 1) . Table 3 presents the demographic and baseline clinical characteristics for all participants available for study at wave 3. The diagnostic groups differed on the basis of level of education, proportion of participants from a non-Englishspeaking background, baseline levels of employment, depression, and MMSE scores.
Relative to undiagnosed participants, those with a diagnosis of either stable or unstable MCI/MCD had significantly lower education, lower baseline MMSE scores, and were more likely to be of a non-English-speaking background (6.2% vs 16.0-31.0%). In addition, a stable diagnosis of MCI/MCD was associated with lower rates of baseline employment (13. Abbreviations: MCD, mild cognitive disorder; MCI, mild cognitive impairment.
NOTE. Totals for diagnosis groups marked in bold. *Percentages based on prevalent cases during the 8-year study period (MCD: n 5 149; MCI: n 5 93).
y Stability of classification is defined as consecutive diagnoses across multiple assessments [34] without reversion to normalcy [35, 36] . 
Clinical and demographic factors associated with diagnostic stability over 8 years
Comparisons of stable and unstable MCD and MCI groups are shown in Table 4 . Diagnostic stability for MCD was associated with lower baseline MMSE scores and increased frequency of neurological disorders. Diagnostic stability for MCI was associated with a higher Framingham cardiovascular 10-year risk profile calculated at baseline and history of neurological disorder. None of the other potential explanatory influences on cognitive fluctuation differentiated diagnostic stability. Participants categorized as stable were also significantly more likely to report memory complaints at baseline relative to those with unstable MCD diagnosis.
Impact of cognitive impairment on memory complaints and IADLs
Impact of cognitive impairment was evaluated by examining medical consultations related to memory, memory complaints, and problems with IADLs (Table 5 ). The stable MCD group had higher rates of reporting they had consulted a doctor about their memory in wave 2, and higher rates of reporting memory interfering with their daily activities in both waves 1 and 2, relative to the undiagnosed group as well as to the unstable MCD group.
Participants with a stable MCI or MCD diagnosis at wave 3 reported more difficulties reading maps, shopping, making telephone calls, and taking medications. All groups reported low levels of problems with meal preparation and grocery shopping.
Discussion
The current study adds to the two previous reports of MCI and any MCD in this sample [3, 4] to provide results Abbreviations: MCD, mild cognitive disorder; MCI, mild cognitive impairment; NS, not significant; IADLs, instrumental activities of daily living. *P , .05, pairwise comparisons with undiagnosed group. characterizing progression to MCD over 8 years in a relatively young cohort. There are several important contributions from this study, including the reporting of incidence rates of MCD in this age group, evaluation of stability of diagnoses, and documentation of the impact of MCD on everyday life. After 8 years of follow-up, approximately 10% of this sample age 68 to 72 years at wave 3 had MCD after correcting statistically for false negatives and attrition. As expected from the younger age sample, incidences of MCI and any MCD were less than one third of the 63.6/1000 recently reported in the Mayo Clinic Study of Aging for a sample age 70 to 89 years at baseline [1] . The incidence rates were also at the lower end of the range reported in a recent review [37] . These rates are likely to underestimate the true level of MCD in the population because the sample had relatively few participants with a low level of education, which is the strongest risk factor for MCI [38] . Moreover, there is greater attrition among participants with cognitive disorders in longitudinal studies [39] , particularly at older ages [40] . Previous studies have also found that the prevalence of MCI is determined by the criteria used [41] . As noted by Petersen and colleagues [42] and Ritchie [43] , epidemiologic study samples include far greater heterogeneity than clinical samples.
Approximately half of all diagnoses in this age group are unstable. Only five participants with MCD converted to dementia during our 8 years of follow-up, which is close to the low rate of progression reported in another study that commenced at age 60 [44] , and was lower than the progression rates reported for studies with older age ranges [42] . These results emphasize the importance of considering the age of the sample when evaluating rates of progression from MCI to dementia. Although participants received clinical diagnoses and reported difficulties in IADLs, MMSE scores were not low.
The clinical indicators of stability of diagnosis included higher levels of depression at baseline and lower MMSE scores. Unlike previous studies, we did not find that the APOE genotype was associated with MCI [45] , and this may be a result of the heterogeneity in our epidemiologic sample. However, 50% of the eight dementia cases had at least one e4 allele, and further follow-up of the cohort will determine whether higher rates of conversion are found among APOE-positive MCD-classified participants.
The characteristics of participants at risk of cognitive impairment were consistent with the literature. Our finding of baseline depression being higher in participants converting to MCI is consistent with previous research showing that late-life depression is associated with increased risk of AD and dementia [46, 47] . Our finding of a higher Framingham risk score at baseline in the MCD group is consistent with previous research from the Whitehall study [32] linking this measure with poorer cognitive function and cognitive decline in men. Similar to the Mayo study [1] , we found that low education and males were at increased risk. What is particularly interesting in relation to the protective effect of education is that the mean difference in years of education between those with MCI/MCD and cognitively normal subjects is that it only differed by 2 years. Moreover, this difference occurred among groups with relatively high levels of education (approximately 12 years vs approximately 14 years).
This study also documents the impact of MCDs on everyday function in adults in their 60s. Consistent with other studies in older samples, impairment in some but not all IADLs was found [48] , indicating that these adults living in the community already experience disability associated with their cognitive disorder. The greater level of impairment in IADLs in the groups with stable diagnoses is consistent with previous research indicating that impairment in IADL predicts faster progression to AD and greater brain atrophy [49] . Compared with the normally aging participants in our study, we found that the MCD group reported higher rates of memory problems interfering with their everyday lives, lower rates of employment, and higher rates of difficulties with IADLs [49] . Criteria for MCI include minimal impairment on complex instrumental functions, and this was established during diagnosis using the Informant Questionnaire for Cognitive Decline in the Elderly and an informant interview. Our findings indicate that those with stable MCD are aware of and more likely to endorse difficulties with complex IADLs relative to the healthy population. The items used to assess IADLs in this study were drawn from the U.S. Health and Retirement Study [25] and may have been more sensitive to impairment in higher level IADLs than items designed for clinical use when impairment is greater. Hence, even in this relatively highly educated cohort, a small proportion experience disability in their 60s as a result of cognitive impairment.
Limitations included sample attrition and a primarily white and highly educated population. Strengths of this study include the population-based sample of relatively young age, a narrow cohort design that allows for aging effects to be studied distinct from cohort effects, the availability of 8 years of follow-up data, and the thorough clinical assessment and consensus diagnosis by clinicians using published criteria. We also used statistical models with bootstrapping to minimize error in our prevalence estimates, adjusted for false negatives, and evaluated statistically the impact of sample attrition on incidence.
The detection of MCI in this younger age group suggests that a proportion of those diagnosed in the older cohort studies may have been impaired for many years, and hence the duration of the clinically detectable MCI phase may be longer than previously considered. This is consistent with the model of biomarkers of AD showing disease progression decades prior to diagnosis [50] . We conclude that MCDs in individuals in their 60s occur in at least 10% of the population and are likely to be heterogeneous in terms of their etiology and long-term prognosis, but may cause a significant impact on everyday life.
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